In patients on prolonged HAART, a significant pool of HIV infected CD4 T cells are HIV-specific

AIDS

Volumn 16, Issue 13, 2002, Pages 1749-1754

  Demoustier, Audrey ^a   Gubler, Brigitte ^a   Lambotte, Olivier ^a   De Goër, Marie Ghislaine ^a   Wallon, Christine ^a   Goujard, Cécile ^a   Delfraissy, Jean François ^a   Taoufik, Yassine ^a  

^a INSERM   (France)

Author keywords

Activation; CD4 T cells; HAART; Latency; Specificity; Virus production

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INDINAVIR; LAMIVUDINE; NEF PROTEIN; STAVUDINE; TUBERCULIN; VIRUS PROTEIN; VIRUS RNA; ZALCITABINE;

ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY CELL; MONONUCLEAR CELL; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; T LYMPHOCYTE; VIROGENESIS; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; TIME FACTORS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0037032068     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200209060-00006     Document Type: Article

References (31)

1. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
2. Perelson AS, Essunger P, Cao Y et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
3. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998, 280:67-71.
4. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000, 18:665-708.
5. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
6. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-300.
7. Chun TW, Stuyver L, Mizell SB. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997, 94:13193-13197.
8. Finzi D, Blankson ], Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 1999, 5:512-517.
9. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999, 282:1627-1632.
10. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nature Med 2000, 6:76-81.
11. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-1622.
12. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340:1605-1613.
13. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, Delfraissy JF. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquit Immune Defic Syndr 2000, 23:114-119.
14. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
15. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
16. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med 1999, 5:518-525.
17. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000, 97:3382-3387.
18. Blankson JN, Gallant JE, Siliciano RF. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis 2001, 183:657-661.
19. Veazey RS, Tham IC, Mansfield KG, et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol 2000, 74:57-64.
20. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS. Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 1990, 87:6058-6062.
21. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002, 76: 4138-4144.
22. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002, 76:3739-3747.
23. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998, 188:83-91.
24. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998, 188:2205-2213.
25. Picker LJ, Maino VC. The CD4(+) T cell response to HIV-1. Curr Opin Immunol 2000, 12:381-386.
26. Wilson JD, Imami N, Watkins A, et al. Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 2000, 182:792-798.
27. Dybul M., Mercier G, Belson M, et al. CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness. J Immunol 2000, 165:1685-1691.
28. Yassine Diab B, Younes S, Breton G, et al. Identification of HIV-specific CD4+ T cells in peripheral blood of HIV-1 infected individuals by tetrameric HLA-DR molecules covalently complexed with peptides. First IAS Conference on HIV Pathogenesis and AIDS. Buenos Aires, July 2001 [abstract 82:11].
29. Leng Q, Bentwich Z, Magen E, Kalinkovich A, Borkow G. CTLA-4 upregulation during HIV infection: association with anergy and possible target for immune reconstitution. AIDS 2002, 16:519-29.
30. Colovai Al, Liu Z, Ciubotariu R, Lederman S, Cortesini R, Suciu-Foca N. Induction of xenoreactive CD4+ T cell anergy by suppressor CD8+ CD28- T cells. Transplantation 2001, 69: 1304-1310.
31. Ciubotariu R, Vasilescu R, Ho E, et al. Detection of T suppressor cells in patients with organ allografts. Hum Immunol 2001, 62:15-20.